AdventHealth Orlando, Orlando (United States of America)
Follow
Contributor content
Presentation
Effects of the GLP-1 receptor agonist, semaglutide, on heart failure outcomes: a pre-specified analysis of the FLOW trial in participants with type 2 diabetes and chronic kidney disease
